Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis.

Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research - 1 Oct 2010

Vandenbroeck Koen, Comabella Manuel

Abstract excerpt

Interferon-beta (IFN-β) is one of the main first-line disease-modifying drugs indicated for the treatment of multiple sclerosis (MS). The drug exhibits only limited effectiveness, and does not produce clinical benefits in around 20%-50% of patients. The availability of biomarkers would be beneficial for identification of patients at high risk of treatment failure, before initiation of therapy. Over the last 5...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interferon-beta
Share to Multiple Sclerosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 20836710
DOI: 10.1089/jir.2010.0085

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis.PMID 20836710Read ↗

Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers.Semantic proximity Read ↗

Pharmacogenomics of interferon-β in multiple sclerosis: what has been accomplished and how can we ensure future progress?Semantic proximity Read ↗

The role of non-HLA single nucleotide polymorphisms in multiple sclerosis susceptibility.Semantic proximity Read ↗

Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.Semantic proximity Read ↗

Analysis of Association Between Genetic Heterogeneity of Interferon Beta Receptor Promoter and Therapeutic Response to Interferon-beta in a Patient with Multiple SclerosisSemantic proximity Read ↗

Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.Semantic proximity Read ↗

Pharmacogenetics of multiple sclerosisSemantic proximity Read ↗

Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.Semantic proximity Read ↗

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.Semantic proximity Read ↗

Association study of promoter polymorphisms of interferon alpha and beta receptor subunit 1 (IFNAR1) gene and therapeutic response to interferon-beta in patients with multiple sclerosis.Semantic proximity Read ↗

IFN-beta pharmacogenomics in multiple sclerosis.Semantic proximity Read ↗

Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.